BRIT J CANCER 2019 10.1038/s41416-019-0618-z
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
Sim1, SH; Park, IH; Jung, KH; Kim, SB; Ahn, JH; Lee, KH; Im, SA; Im, YH; Park, YH; Sohn, J; Kim, YJ; Lee, S; Kim, HJ; Chae, YS; Park, KH; Nam, BH; Lee, KS; Ro, J

LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Park1, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Heo1, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH

CANCER 2019 10.1002/cncr.32392
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE
Perez1, EA; Barrios, C; Eiermann, W; Toi, M; Im, YH; Conte, P; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Petersen, JA; De Haas, S; Hoersch, S; Patre, M; Ellis, PA

CANCER COMMUN 2019 10.1186/s40880-019-0375-7
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Kim1, JY; Park, S; Im, SA; Kim, SB; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH; Park, YH

BMC CANCER 2019 10.1186/s12885-019-5687-0
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Perez1, EA; de Haas, SL; Eiermann, W; Barrios, CH; Toi, M; Im, YH; Conte, PF; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Stanzel, S; Patre, M; Ellis, PA

CANCER RES TREAT 2019 10.4143/crt.2018.262
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
Kim1, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF

CANCER RES TREAT 2019 10.4143/crt.2018.342
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Kim1, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH

ONCOLOGIST 2019 10.1634/theoncologist.2018-0184
Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
Kang1, D; Kim, IR; Choi, EK; Im, YH; Park, YH; Ahn, JS; Lee, JE; Nam, SJ; Lee, HK; Park, JH; Lee, DY; Lacouture, ME; Guallar, E; Cho, J

SCI REP-UK 2019 10.1038/s41598-019-41098-0
Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator
Oh1, BY; Shin, HT; Yun, JW; Kim, KT; Kim, J; Bae, JS; Cho, YB; Lee, WY; Yun, SH; Park, YA; Park, YH; Im, YH; Lee, J; Joung, JG; Kim, HC; Park, WY

ONCOL LETT 2019 10.3892/ol.2018.9754
Clinical features and prognosis of breast cancer with gastric metastasis
Hong1, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH

BMC CANCER 2019 10.1186/s12885-018-5258-9
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
Kim1, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH

BREAST CANCER RES TR 2019 10.1007/s10549-018-4981-x
A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients
Hwang1, HW; Jung, H; Hyeon, J; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Choi, M; Cho, SY; Cho, EY

HERED CANCER CLIN PR 2019 10.1186/s13053-018-0103-3
The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans
Kim1, H; Choi, DH; Park, W; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Jung, BY

J BREAST CANC 2018 10.4048/jbc.2018.21.e48
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
Seo1, Y; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Cho, SY; Cho, EY

INT J CANCER 2018 10.1002/ijc.31651
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Park1, YH; Lee, KH; Sohn, JH; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Ahn, JS; Kim, TY; Kim, GM; Park, IH; Kim, SB; Kim, SH; Han, HS; Im, YH; Ahn, JH; Kim, JY; Kang, J; Im, SA

EUR J CANCER 2018 10.1016/j.ejca.2018.08.004
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Kim1, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH

CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010
Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment
Cho1, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S

BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z
Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
Kim1, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH

ANN ONCOL 2018 10.1093/annonc/mdy257
Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
Ettl1, J; Quek, RGW; Lee, KH; Rugo, HS; Hurvitz, S; Goncalves, A; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Markova, D; Bhattacharyya, H; Hannah, AL; Eiermann, W; Blum, JL; Litton, JK

NEW ENGL J MED 2018 10.1056/NEJMoa1802905
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton1, JK; Rugo, HS; Ettl, J; Hurvitz, SA; Goncalves, A; Lee, KH; Fehrenbacher, L; Yerushalmi, R; Mina, LA; Martin, M; Roche, H; Im, YH; Quek, RGW; Markova, D; Tudor, IC; Hannah, AL; Eiermann, W; Blum, JL

LANCET ONCOL 2018 10.1016/S1470-2045(18)30292-4
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Tripathy1, D; Im, SA; Colleoni, M; Franke, F; Bardia, A; Harbeck, N; Hurvitz, SA; Chow, L; Sohn, J; Lee, KS; Campos-Gomez, S; Vazquez, RV; Jung, KH; Babu, KG; Wheatley-Price, P; De Laurentiis, M; Im, YH; Kuemmel, S; El-Saghir, N; Liu, MC; Carlson, G; Hughes, G; Diaz-Padilla, I; Germa, C; Hirawat, S; Lu, YS

J BREAST CANC 2018 10.4048/jbc.2018.21.2.206
Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?
Cho1, WK; Park, W; Choi, DH; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY

Oncoimmunology 2018 10.1080/2162402X.2018.1466768
Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
Park1, SE; Park, K; Lee, E; Kim, JY; Ahn, JS; Im, YH; Lee, C; Jung, H; Cho, SY; Park, WY; Cristescu, R; Park, YH

NAT COMMUN 2018 10.1038/s41467-018-04129-4
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan1, ZY; Ding, Y; Kim, J; Jung, HH; Chung, W; Lal, S; Cho, S; Fernandez-Banet, J; Lee, SK; Kim, SW; Lee, JE; Choi, YL; Deng, S; Kim, JY; Ahn, JS; Sha, Y; Mu, XJ; Nam, JY; Im, YH; Lee, S; Park, WY; Nam, SJ; Park, YH

ANN ONCOL 2018 10.1093/annonc/mdy034
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients
Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J

BREAST CANCER RES TR 2018 10.1007/s10549-017-4628-3
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Ponde1, N; Bradbury, I; Lambertini, M; Ewer, M; Campbell, C; Ameels, H; Zardavas, D; Di Cosimo, S; Baselga, J; Huober, J; Izquierdo, M; Fumagalli, D; Bozovic-Spasojevic, I; Maetens, M; Harbeck, N; Pusztai, L; Berghorn, M; Im, YH; Borrego, MR; Chen, DR; Rodeheffer, R; Piccart, M; Suter, T; de Azambuja, E

ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12681
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline
Sohn1, BS; Kim, SB; Ahn, JH; Jung, KH; Kim, J; Lee, KS; Ro, J; Im, SA; Im, YH; Song, HS; Park, HS; Chung, HC

NAT COMMUN 2017 10.1038/s41467-017-01470-y
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

ANN ONCOL 2017 10.1093/annonc/mdx406
Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial
Miles1, D; Im, YH; Fung, A; Yoo, B; Knott, A; Heeson, S; Beattie, MS; Swain, SM

EUR J CANCER 2017 10.1016/j.ejca.2017.10.002
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park1, YH; Im, SA; Kim, SB; Sohn, JH; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, JY; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH

J BREAST CANC 2017 10.4048/jbc.2017.20.3.286
NanoString nCounter (R) Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry
Hyeon1, J; Cho, SY; Hong, ME; Kang, SY; Doe, I; Im, YH; Cho, EY

ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12652
Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy
Kim1, H; Park, W; Huh, SJ; Choi, DH; Noh, JM; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Cho, EY

BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy
Kim1, JY; Ok, ON; Seo, JJ; Lee, SH; Ahn, JS; Im, YH; Park, YH

ONCOTARGET 2017 10.18632/oncotarget.17653
Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
Kim1, JY; Lee, E; Park, K; Park, WY; Jung, HH; Ahn, JS; Im, YH; Park, YH

Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881.
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
Kim JY11, Lee E2, Park K2, Park WY2, Jung HH3, Ahn JS1, Im YH1,4, Park YH1,4,3.

Cancer Res Treat. 2017 Apr;49(2):423-429. doi: 10.4143/crt.2016.191. Epub 2016 Aug 3.
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
Park YH11, Kim TY2, Im YH1, Lee KS3, Park IH3, Sohn J4, Lee SH4, Im SA2, Kim JH5, Kim SH5, Lee SJ6, Koh SJ7, Lee KH8, Choi YJ9, Cho EK10, Lee S11, Kang SY12, Seo JH13, Kim SB14, Jung KH14.

Breast Cancer Res. 2017 Feb 9;19(1):16. doi: 10.1186/s13058-017-0806-9.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Bianchini G11, Kiermaier A2, Bianchi GV3, Im YH4, Pienkowski T5, Liu MC6, Tseng LM7, Dowsett M8, Zabaglo L9, Kirk S10, Szado T11, Eng-Wong J11, Amler LC11, Valagussa P12, Gianni L13.

Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6.
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer
Park KH11, Lee S2, Park JH3, Kang SY4, Kim HY5, Park IH6, Park YH7, Im YH7, Lee HJ8, Park S9, Lee SI10, Jung KH11, Kim YS12, Seo JH13.

Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414.
The effect of androgen receptor expression on clinical characterization of metastatic breast cancer
Kim JY11, Park K2, Lee E2, Jung HH3, Ahn JS1, Im YH1,4, Park WY2,5, Park YH1,4,3.

J Clin Oncol. 2017 Jan 10;35(2):141-148. Epub 2016 Nov 7.
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Perez EA11, Barrios C1, Eiermann W1, Toi M1, Im YH1, Conte P1, Martin M1, Pienkowski T1, Pivot X1, Burris H 3rd1, Petersen JA1, Stanzel S1, Strasak A1, Patre M1, Ellis P1.

Breast Cancer Res Treat. 2016 Dec;160(3):475-489. doi: 10.1007/s10549-016-4008-4. Epub 2016 Oct 11.
Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems
Choi M11, Park YH2, Ahn JS2, Im YH2, Nam SJ3, Cho SY4, Cho EY5.

Cancer Res Treat. 2016 Oct;48(4):1373-1381. Epub 2016 Mar 23.
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
Kim SH11, Jung KH2, Kim TY3, Im SA3, Choi IS4, Chae YS5, Baek SK6, Kang SY7, Park S8, Park IH9, Lee KS9, Choi YJ10, Lee S11, Sohn JH11, Park YH12, Im YH12, Ahn JH2, Kim SB2, Kim JH1.

Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18.
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
Kim JY11, Park K2, Jung HH3, Lee E2, Cho EY4, Lee KH5, Bae SY6, Lee SK6, Kim SW6, Lee JE6, Nam SJ6, Ahn JS1, Im YH1,3, Park YH1,3.

PLoS One. 2016 Oct 31;11(10):e0165814. doi: 10.1371/journal.pone.0165814. eCollection 2016.
Body Mass Index with Tumor F-18-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer
Hyun SH11, Ahn HK2, Lee JH1, Choi JY1, Kim BT1, Park YH3, Im YH3, Lee JE4, Nam SJ4, Lee KH1.

Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11.
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Kim HK11, Ham JS1, Byeon S1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Lee JY1, Lim SH1, Kim HS1, Kim JY1, Lee JE2, Kim SW2, Nam SJ2, Lee SK2, Bae SY2, Ahn JS1, Im YH1, Park YH1.

Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035.
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency
Jung HH11, Lee SH2, Kim JY2, Ahn JS2, Park YH1,2,3, Im YH2,3.

SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804
The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
Kim JY1, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH

Medicine (Baltimore). 2016 Aug;95(32):e4266. doi: 10.1097/MD.0000000000004266.
Relation between primary tumor FDG avidity and site of first distant metastasis in patients with breast cancer
Lim CH11, Moon SH, Cho YS, Im YH, Choe YS, Kim BT, Lee KH.

Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623.
Gene Expression Profiling of Breast Cancer Brain Metastasis
Lee JY11, Park K2, Lee E2, Ahn T2, Jung HH3, Lim SH1, Hong M4, Do IG4, Cho EY4, Kim DH5, Kim JY1, Ahn JS1, Im YH1,2, Park YH1,3.

Clin Breast Cancer. 2016 Jun;16(3):e15-21. doi: 10.1016/j.clbc.2015.11.008. Epub 2015 Dec 11.
Limited Supraclavicular Radiation Field in Breast Cancer With >= 10 Positive Axillary Lymph Nodes
Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.

J Breast Cancer. 2016 Jun;19(2):169-75. doi: 10.4048/jbc.2016.19.2.169. Epub 2016 Jun 24.
Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes
Kim SW11, Choi DH2, Huh SJ2, Park W2, Nam SJ3, Kim SW3, Lee JE3, Im YH4, Ahn JS4, Park YH4.

Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Gianni L11, Pienkowski T2, Im YH3, Tseng LM4, Liu MC5, Lluch A6, Starosławska E7, de la Haba-Rodriguez J8, Im SA9, Pedrini JL10, Poirier B11, Morandi P12, Semiglazov V13, Srimuninnimit V14, Bianchi GV15, Magazzu D16, McNally V17, Douthwaite H17, Ross G18, Valagussa P16.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23.
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Piccart-Gebhart M11, Holmes E1, Baselga J1, de Azambuja E1, Dueck AC1, Viale G1, Zujewski JA1, Goldhirsch A1, Armour A1, Pritchard KI1, McCullough AE1, Dolci S1, McFadden E1, Holmes AP1, Tonghua L1, Eidtmann H1, Dinh P1, Di Cosimo S1, Harbeck N1, Tjulandin S1, Im YH1, Huang CS1, Dieras V1, Hillman DW1, Wolff AC1, Jackisch C1, Lang I1, Untch M1, Smith I1, Boyle F1, Xu B1, Gomez H1, Suter T1, Gelber RD1, Perez EA1.

Cancer Res Treat. 2016 Apr;48(2):499-507. doi: 10.4143/crt.2015.089. Epub 2015 Jul 14.
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
Yoo C11, Kim SB1, Ro J2, Im SA3, Im YH4, Kim JH5, Ahn JH1, Jung KH1, Song HS6, Kang SY7, Park HS8, Chung HC9.

Lancet Oncol. 2016 Mar;17(3):357-66. doi: 10.1016/S1470-2045(15)00540-9. Epub 2016 Jan 26.
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Harbeck N11, Huang CS2, Hurvitz S3, Yeh DC4, Shao Z5, Im SA6, Jung KH7, Shen K8, Ro J9, Jassem J10, Zhang Q11, Im YH12, Wojtukiewicz M13, Sun Q14, Chen SC15, Goeldner RG16, Uttenreuther-Fischer M16, Xu B17, Piccart-Gebhart M18; LUX-Breast 1 study group.

BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
Kim JY11, Jung HH2, Do IG3, Bae S4, Lee SK5, Kim SW6, Lee JE7, Nam SJ8, Ahn JS9, Park YH10,11, Im YH12,13.

PLoS One. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432. eCollection 2016.
The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
Lee JY11, Lim SH1, Lee MY1, Kim HS1, Ahn JS1, Im YH1, Park YH1.

Clin Breast Cancer. 2015 Dec;15(6):512-8. doi: 10.1016/j.clbc.2015.06.004. Epub 2015 Jun 18.
Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments
Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.

Ann Oncol. 2015 Dec;26(12):2429-36. doi: 10.1093/annonc/mdv395. Epub 2015 Sep 19.
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
Bianchini G11, Pusztai L2, Pienkowski T3, Im YH4, Bianchi GV5, Tseng LM6, Liu MC7, Lluch A8, Galeota E1, Magazzu D9, de la Haba-Rodriguez J10, Oh DY11, Poirier B12, Pedrini JL13, Semiglazov V14, Valagussa P9, Gianni L15.

Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192.
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer
Lee JY11, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.

Ann Surg Oncol. 2015 Oct;22(11):3481-8. doi: 10.1245/s10434-015-4399-1. Epub 2015 Feb 5.
The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women
Kim J11, Han W2, Jung SY3, Park YH4, Moon HG5, Ahn SK6, Lee JW7, Kim MK5, Kim JJ5, Lee ES5, You TK1, Kang HS3, Lee ES3, Ro J3, Lee JE4, Nam SJ4, Yim YH4, Park IA5, Noh DY5.

Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184.
Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
Park YH11,2, Shin HT3, Jung HH2, Choi YL3, Ahn T3, Park K3, Lee A4, Do IG5, Kim JY1,2, Ahn JS1, Park WY3, Im YH1,2.

BMC Cancer. 2015 Oct 14;15:693. doi: 10.1186/s12885-015-1716-9.
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
Lee SJ11, Kim S2, Kim M3, Lee J4, Park YH5, Im YH6, Park SH7.

Cancer Res Treat. 2015 Oct;47(4):765-73. doi: 10.4143/crt.2014.168. Epub 2015 Jan 13.
Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer
Lee JY11, Lim SH1, Lee MY1, Kim H1, Kim M1, Kim S1, Jung HA1, Sohn I2, Gil WH3, Lee JE3, Kim SW3, Nam SJ3, Ahn JS1, Im YH1, Park YH1.

Oncotarget. 2015 Sep 15;6(27):24499-510.
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
Park K11, Choi MK2, Jung HH3, Do IG4, Lee KH5, Ahn T1, Kil WH6, Kim SW6, Lee JE6, Nam SJ6, Kim DH7, Ahn JS2, Im YH2,3, Park YH2,3.

Cancer?Chemother Pharmacol.?2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22.
Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer
Choi MK11,?Park YH,?Kil WH,?Lee JE,?Nam SJ,?Ahn JS,?Im YH.

Oncology.?2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4.
Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers
Park YH11,?Im SA,?Cho EY,?Ahn JH,?Woo SY,?Kim S,?Keam B,?Lee JE,?Han W,?Nam SJ,?Park IA,?Noh DY,?Yang JH,?Ahn JS,?Im YH.

Cancer Res Treat. 2014 Apr;46(2):200-3. doi: 10.4143/crt.2014.46.2.200. Epub 2014 Apr 22.
Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma
Park LC11, Jeong JY2, Ji JH3, Park S3, Ahn JS3, Im YH3, Park YH3.

Eur J Cancer. 2014 Mar;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028. Epub 2013 Dec 18.
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
Lee SY11, Im SA2, Park YH3, Woo SY4, Kim S4, Choi MK5, Chang W5, Ahn JS5, Im YH5.

Ann Oncol. 2014 Feb;25(2):346-51. doi: 10.1093/annonc/mdt476. Epub 2013 Dec 29.
Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients
Cho J11, Choi EK, Kim IR, Im YH, Park YH, Lee S, Lee JE, Yang JH, Nam SJ.

Br J?Cancer.?2014 Jan 21;110(2):384-91. doi: 10.1038/bjc.2013.757. Epub 2013 Dec 17.
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
Park YH11,?Jung HA1,?Choi MK1,?Chang W1,?Choi YL2,?Do IG2,?Ahn JS1,?Im YH1.

Biochem Biophys Res Commun.?2013 Sep 20;439(2):275-9. doi: 10.1016/j.bbrc.2013.08.043. Epub 2013 Aug 21.
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway
Park YH11,?Jung HH,?Ahn JS,?Im YH.

Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02

Neuro Oncol.?2012 Aug;14(8):1105-13. doi: 10.1093/neuonc/nos137. Epub 2012 Jun 11.
Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram
Ahn HK11,?Lee S,?Park YH,?Sohn JH,?Jo JC,?Ahn JH,?Jung KH,?Park S,?Cho EY,?Lee JI,?Park W,?Choi DH,?Huh SJ,?Ahn JS,?Kim SB,?Im YH.

Breast?Cancer Res Treat.?2012 May;133(1):247-55. doi: 10.1007/s10549-012-1956-1. Epub 2012 Jan 21.
Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy
Park YH11,?Im SA,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Ahn JS,?Im YH.

Implications of Different CA 15-3 Levels according to Breast Cancer Subtype at Initial Diagnosis of Recurrent or Metastatic Breast Cancer

Breast?Cancer?Res Treat.?2011 Oct;129(3):809-17. doi: 10.1007/s10549-011-1682-0. Epub 2011 Jul 23.
Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations
Lee S11,?Ahn HK,?Park YH,?Nam do H,?Lee JI,?Park W,?Choi DH,?Huh SJ,?Park KT,?Ahn JS,?Im YH.

Cancer Chemother Pharmacol. 2011 Sep;68(3):743-51. doi: 10.1007/s00280-010-1545-0. Epub 2010 Dec 18.
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
Lee SJ11, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH.

Cancer?Chemother Pharmacol.?2011 Sep;68(3):753-61. doi: 10.1007/s00280-010-1548-x. Epub 2010 Dec 18.
Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)
Cho EY11,?Chang MH,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Park YH,?Ahn JS,?Im YH.

Oncology.?2011;81(1):55-62. doi: 10.1159/000331417. Epub 2011 Sep 16.
Patterns of Skin and Soft Tissue Metastases from Breast Cancer according to Subtypes: Relationship between EGFR Overexpression and Skin Manifestations
Kong JH11,?Park YH,?Kim JA,?Kim JH,?Yun J,?Sun JM,?Won YW,?Lee S,?Kim ST,?Cho EY,?Ahn JS,?Im YH.

Ann Oncol.?2011 Jul;22(7):1554-60. doi: 10.1093/annonc/mdq617. Epub 2011 Jan 17.
Clinical relevance of TNM staging system according to breast cancer subtypes
Park YH11,?Lee SJ,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Shin JH,?Ko EY,?Han BK,?Ahn JS,?Im YH.

Cancer?Res Treat.?2011 Jun;43(2):89-95. doi: 10.4143/crt.2011.43.2.89. Epub 2011 Jun 30.
Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
Lee SJ11,?Park S,?Ahn HK,?Yi JH,?Cho EY,?Sun JM,?Lee JE,?Nam SJ,?Yang JH,?Park YH,?Ahn JS,?Im YH.

Biochem Biophys Res Commun.?2011 Apr 22;407(4):680-6. doi: 10.1016/j.bbrc.2011.03.075. Epub 2011 Apr 2.
ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression
Park S11,?Jung HH,?Park YH,?Ahn JS,?Im YH.

Br J?Cancer.?2011 Feb 15;104(4):559-63. doi: 10.1038/bjc.2011.4. Epub 2011 Feb 1.
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
Yun J11,?Kim KH,?Kang ES,?Gwak GY,?Choi MS,?Lee JE,?Nam SJ,?Yang JH,?Park YH,?Ahn JS,?Im YH.

Med Oncol.?2010 Dec;27(4):1234-8. doi: 10.1007/s12032-009-9364-z. Epub 2009 Nov 19.
Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)
Choi MK11,?Park YH,?Hong JY,?Park HC,?Ahn YC,?Kim K,?Shim YM,?Kang WK,?Park K,?Im YH.

CA 15-3 kinetics: clinical implication of CA 15-3 surge in metastatic breast cancer
Br J Cancer.?2010 Sep 7;103(6):845-51. doi: 10.1038/sj.bjc.6605831. Epub 2010 Aug 10.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
Lee S11,?Park YH,?Kim KH,?Cho EY,?Ahn YC,?Kim K,?Shim YM,?Ahn JS,?Park K,?Im YH.

Cancer?Chemother Pharmacol.?2010 Aug;66(3):507-16. doi: 10.1007/s00280-009-1190-7. Epub 2009 Dec 3.
Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status
Park YH11,?Lee S,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Ahn JS,?Im YH.

Mol Cancer Res.?2010 Jul;8(7):1037-47. doi: 10.1158/1541-7786.MCR-09-0469. Epub 2010 Jun 15.
Matrix Metalloproteinase-1 Expression Can Be Upregulated through Mitogen-Activated Protein Kinase Pathway under the Influence of Human Epidermal Growth Factor Receptor 2 Synergized with Estrogen Receptor
Jung HH11,?Park YH,?Jun HJ,?Kong J,?Kim JH,?Kim JA,?Yun J,?Sun JM,?Won YW,?Lee S,?Kim ST,?Ahn JS,?Im YH.

Breast?Cancer?Res Treat.?2010 Feb;119(3):653-61. doi: 10.1007/s10549-009-0665-x.
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (<= 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment
Park YH11,?Kim ST,?Cho EY,?Choi YL,?Ok ON,?Baek HJ,?Lee JE,?Nam SJ,?Yang JH,?Park W,?Choi DH,?Huh SJ,?Ahn JS,?Im YH.

Breast Cancer?Res Treat.?2009 Nov;118(1):89-97. doi: 10.1007/s10549-009-0377-2. Epub 2009 Mar 26.
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
Kim HS11,?Park YH,?Park MJ,?Chang MH,?Jun HJ,?Kim KH,?Ahn JS,?Kang WK,?Park K,?Im YH.

Br J?Cancer.?2009 Mar 24;100(6):894-900. doi: 10.1038/sj.bjc.6604941. Epub 2009 Feb 24.
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
Park YH11,?Park MJ,?Ji SH,?Yi SY,?Lim DH,?Nam DH,?Lee JI,?Park W,?Choi DH,?Huh SJ,?Ahn JS,?Kang WK,?Park K,?Im YH.